Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals
This article was originally published in The Pink Sheet Daily
Eisai and Astellas execs tell BIO attendees that forming strong initial partnerships provides a basis for expanding alliances into new products and geographies.
You may also be interested in...
Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.